CDK4 and heart failure: Considering that the median time-to-the development of heart failure following CDK4/6 inhibitor administration is a few months, as observed in previous research and this study, it is warranted to carefully monitor signs and symptoms of heart failure during follow-up until more research findings and relevant management strategies are accumulated [13].